Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mart Ustav

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Nature Communications|February 3, 2024
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axisXuanming Guo, Pallavi Asthana, Lixiang Zhai, et al.
Protein Science : a Publication of the Protein Society|January 20, 2026
Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivoJarrett J Adams, Levi L Blazer, Jacky Chung, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2James Brett Case, Paul W Rothlauf, Rita E Chen, et al.
Cell Host & Microbe|August 1, 2020
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2James Brett Case, Paul W Rothlauf, Rita E Chen, et al.
Journal of Molecular Biology|July 30, 2021
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape MutationsShane Miersch, Zhijie Li, Reza Saberianfar, et al.
SSRN|July 28, 2020
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2James Brett Case, Paul W Rothlauf, Rita E Chen, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape MutationsShane Miersch, Zhijie Li, Reza Saberianfar, et al.
Communications Biology|April 13, 2021
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2Kushal Suryamohan, Devan Diwanji, Eric W Stawiski, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Nature Communications|February 3, 2024
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axisXuanming Guo, Pallavi Asthana, Lixiang Zhai, et al.
Protein Science : a Publication of the Protein Society|January 20, 2026
Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivoJarrett J Adams, Levi L Blazer, Jacky Chung, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2James Brett Case, Paul W Rothlauf, Rita E Chen, et al.
Cell Host & Microbe|August 1, 2020
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2James Brett Case, Paul W Rothlauf, Rita E Chen, et al.
Journal of Molecular Biology|July 30, 2021
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape MutationsShane Miersch, Zhijie Li, Reza Saberianfar, et al.
SSRN|July 28, 2020
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2James Brett Case, Paul W Rothlauf, Rita E Chen, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape MutationsShane Miersch, Zhijie Li, Reza Saberianfar, et al.
Communications Biology|April 13, 2021
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2Kushal Suryamohan, Devan Diwanji, Eric W Stawiski, et al.
Pageof 9